ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

Daily Humidification Improves Quality-of-Life in Phase III Trial

February 28, 2014

Gene Patterns Predict Lymphoma Response To Treatment

June 28, 2002

Diagnosis-Treatment Cidac contract Gets Recompetition Okay

December 16, 1983

NCI Programs: HMO Research Network wins $16 Million Grant for Prevention Studies

July 30, 1999

St. Jude Director Cites Poor Housing’s Toll on Children, March 28, 1971

May 19, 2021

In Brief: Korsmeyer Wins Bristol-Meyers Squibb Award; Lichter Names President-Elect of ASCO

April 18, 1997